Most drugs are covered by multiple patents, with initial patents directed broadly to the compound and later patents directed to increasingly narrower uses of the compound. This provides opportunities for the compound to be approved as a generic drug before expiration of all of the patents, based on a “skinny” label – i.e., a label … Continue Reading
Over the last decade, filings of patent lawsuits in the US rose to unprecedented highs in 2013, and remained high for a while thereafter, but have steadily declined in the last few years. The decline is variously attributed to Inter Partes review (IPR) proceedings established in 2011 under the America Invents Act (AIA) and a … Continue Reading
